AA Amyloidosis from Long-Standing Rheumatoid Arthritis: Choosing a Regimen to Halt Renal Deposition
A single patient whose rheumatoid arthritis has been quiet for eight years while an old disease burden has caught up with her kidneys. The disagreement isn’t whether her arthritis needs to stay controlled — it’s whether controlling it harder, or differently, is the actual lever on what her biopsy just found.
Josephine R., a 66-year-old woman, has kept the same quarter-acre vegetable garden behind her house for over thirty years, though this spring, for the first time, she needed her neighbor’s help turning the soil before planting. She was diagnosed with seropositive rheumatoid arthritis thirty-four years ago, some six years before the first TNF inhibitor was approved for rheumatoid arthritis, and spent most of that first decade on NSAIDs and injectable gold salts alone — undertreated by any current standard, and her hands and feet show it, with the ulnar deviation and forefoot deformity of disease that ran openly active for years before anyone had a better option to offer her. The last eight years, on adalimumab and methotrexate together, have been the quietest her joints have been in her adult life — morning stiffness under fifteen minutes, no new erosions on her last films.
What brought her back sooner than her routine follow-up was ankle swelling she initially blamed on the garden work, and a urinalysis that turned up more protein than either of them expected: a 24-hour collection came back at 1.8 grams, with a creatinine of 0.9 and an estimated GFR of 78 — kidney function still essentially normal, but proteinuria that isn’t. A renal biopsy showed Congo-red-positive deposits with the characteristic apple-green birefringence under polarized light: AA amyloidosis, caught while her renal function is still preserved and the deposit burden, on biopsy, still looks early. Her nephrologist has deferred any renal-specific therapy for now — there is nothing to treat in the kidney itself at this stage, and the only lever runs back through her inflammatory disease. A serum amyloid A level was sent today and hasn’t resulted yet, and that pending number is the one the rest of this turns on. In Lachmann’s 374-patient natural-history cohort, the median SAA among patients whose renal function improved was 6mg/L, against 28mg/L in those whose renal function deteriorated. Whether her arthritis needs to stay controlled is not in question — it obviously does. What that cohort does settle is which of her own two numbers carries more weight today. Her eGFR of 78 puts her inside the subgroup Lachmann could analyze for renal recovery at all — the patients still above a creatinine clearance of 20 — and within that subgroup the risk of reaching dialysis rose roughly fivefold for every doubling of baseline creatinine. Her creatinine of 0.9 is therefore not the number in trouble; it is the margin she still has. It is her SAA, not her kidney function, that decides whether she keeps it.
What the pending lab actually decides
I’d switch her to tocilizumab now. Serum amyloid A is an IL-6-driven hepatic acute-phase reactant, and IL-6 receptor blockade is the most direct lever available on its production. Lachmann et al., in their 2007 natural-history cohort in the New England Journal of Medicine, found that sustained near-normal SAA was the single strongest predictor of renal survival in AA amyloidosis, and case series in rheumatoid-arthritis-associated AA amyloidosis specifically report amyloid regression with tocilizumab. If suppressing SAA is what determines her renal outcome, we should use the drug that suppresses it most reliably.
You’re right that IL-6 blockade is the more direct mechanism on paper — but directness isn’t the same thing as demonstrated benefit in the patient actually in front of us.
Eight years of quiet disease on adalimumab and methotrexate is real evidence that regimen is working for her specifically, and switching risks destabilizing something that’s held for nearly a decade — without yet knowing whether her own SAA is even elevated. Adequately dosed TNF inhibitors can suppress SAA meaningfully too. The question isn’t which drug class is theoretically superior in general; it’s what her own number says today.
Both of those arguments are actually testable by the same lab result we’re waiting on. Lachmann’s cohort tied renal survival to the achieved SAA level, essentially regardless of which drug got a patient there — and the same cohort found the window for a good outcome narrows sharply once GFR starts to fall, which is exactly why acting now, while hers is still 78, matters more than which mechanism gets the credit.
Check today’s SAA before deciding anything. If it’s not already in the near-normal range Lachmann’s data associated with good renal outcomes, switch to tocilizumab now, given the biopsy shows this is still early. If it’s already well controlled on the current regimen, there may be no reason to switch at all — her kidneys may already be on the best trajectory available.
Agreed: today’s SAA result decides the immediate question before any regimen change is made. If elevated, switch to tocilizumab; if already low, continue the current regimen with close renal monitoring — repeat 24-hour protein and eGFR at three months either way.
Not agreed, and left as a real open branch rather than smoothed over:
The plan is straightforward — switch to tocilizumab, both voices agree.
The Rheumatologist would still favor switching preemptively given the amyloidosis diagnosis itself; the Nephrologist would want a second value before changing a regimen that has otherwise worked for eight years.